PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 111.90% | -110.70% | -8.34% | -269.93% | -68.92% |
| Total Depreciation and Amortization | 3.34% | 51.92% | 18.42% | 4.36% | -4.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -75.94% | 29.09% | 2,132.86% | -27.27% | 98.71% |
| Change in Net Operating Assets | -275.10% | 222.75% | 1,737.56% | 110.87% | -137.41% |
| Cash from Operations | -276.83% | 171.74% | 395.93% | -249.50% | -88.66% |
| Capital Expenditure | -341.73% | -100.92% | 198.49% | -8,088.24% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 87.07% | -910.44% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 98.26% | -- | -- | -- | -- |
| Cash from Investing | 95.66% | 71.23% | -161.66% | -12,026.74% | 99.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 33.77% | -163.61% | -20.79% | 0.39% | 0.78% |
| Issuance of Common Stock | -- | 477.83% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.78% | 2,572.53% | -- | -- | -- |
| Cash from Financing | -98.76% | 596.14% | 6,233.70% | -3.40% | 3.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.04% | 554.07% | -35.10% | -6,838.12% | 100.37% |